<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373060</url>
  </required_header>
  <id_info>
    <org_study_id>1941-CL-2001</org_study_id>
    <nct_id>NCT01373060</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of ASP1941 in Healthy Male Taiwanese Subjects</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of ASP1941 in Healthy Male Taiwanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Taiwan, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the safety, tolerability, pharmacokinetics and pharmacodynamics of
      ASP1941 orally administered as single doses to healthy adult male Taiwanese subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subjects will be administered a single dose of ASP1941 or placebo under fasting
      condition. Plasma and urine levels of ASP1941 and glucose will be measured to investigate
      pharmacokinetic and pharmacodynamic properties of ASP1941.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by the incidence of adverse events, vital signs, safety lab tests and 12-lead ECG</measure>
    <time_frame>up to 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of ASP1941 plasma concentration</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (Area under the curve) of ASP1941 plasma concentration</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma glucose</measure>
    <time_frame>baseline and up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in urine glucose</measure>
    <time_frame>baseline and up to 72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy</condition>
  <condition>Pharmacokinetics of ASP1941</condition>
  <arm_group>
    <arm_group_label>ASP1941 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1941</intervention_name>
    <description>oral</description>
    <arm_group_label>ASP1941 group</arm_group_label>
    <other_name>ipragliflozin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight between 50 and 85 kg, and Body Mass Index (BMI) between 17.6 and 26.4
             kg/m2 inclusive

        Exclusion Criteria:

          -  Medical history of metabolic disease, hepatic disease, heart disorder, respiratory
             disease, gastrointestinal disease, renal disease, cerebrovascular disorder, malignant
             tumor, drug allergy and drug/alcohol dependence

          -  Blood pressure, pulse rate, body temperature and 12-lead ECG are outside of the preset
             normal range

          -  Labo test results deviate from preset normal range

          -  Receiving treatment, including medication, within 14 days before the study

          -  Receiving medication in another clinical study or a post-marketing clinical trial
             within 3 months before the study

          -  Donates 500mL of whole blood within 3 months or 250mL within 2 months or blood
             components within 14 days before the study

          -  Drinking more than 45g of alcohol, or smoking more than 20 cigarettes per day

          -  Employed by the sponsor, delegated CRO or the study site

          -  Fasting plasma glucose level of &lt; 70 mg/dL or ≥110 mg/dL or with an HbA1c ≥5.8%

          -  Subjects with positive serology test for Hepatitis B antigen, Hepatitis A virus IgM,
             anti-Hepatitis C virus or anti-Human Immunodeficiency virus-1 or -2
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2011</study_first_submitted>
  <study_first_submitted_qc>June 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2011</study_first_posted>
  <last_update_submitted>October 10, 2011</last_update_submitted>
  <last_update_submitted_qc>October 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP1941</keyword>
  <keyword>ipragliflozin</keyword>
  <keyword>plasma glucose</keyword>
  <keyword>urine glucose</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

